Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014 (2014), Article ID 186212, 10 pages
http://dx.doi.org/10.1155/2014/186212
Clinical Study

Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival

1Skin Cancer Unit, CHU Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093 Nantes, France
2CRCNA, INSERM U892, CNRS 6299, 9 Quai Moncousu, 44093 Nantes, France
3PIMESP-SEB, Hôpital St Jacques, 85 rue St Jacques, 44093 Nantes, France
4Service d’Anatomie et Cytologie Pathologiques, CHU Hôtel-Dieu, 30 boulevard Jean Monnet, 44093 Nantes, France
5Plateforme de Génétique des Cancers, CHU Hôtel-Dieu, 1 Place Alexis Ricordeau, 44000 Nantes, France
6Unité de Thérapie Cellulaire et Génique (UTCG), CHU Hôtel-Dieu, 9 Quai Moncousu, 44093 Nantes, France

Received 19 July 2013; Revised 18 November 2013; Accepted 6 December 2013; Published 8 January 2014

Academic Editor: Ana Parente Pereira

Copyright © 2014 Amir Khammari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Boon, P. G. Coulie, B. J. Van Den Eynde, and P. Van Der Bruggen, “Human T cell responses against melanoma,” Annual Review of Immunology, vol. 24, pp. 175–208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Rosenberg, B. S. Packard, P. M. Aebersold et al., “Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report,” The New England Journal of Medicine, vol. 319, no. 25, pp. 1676–1680, 1988. View at Google Scholar · View at Scopus
  4. R. Wu, M.-A. Forget, J. Chacon et al., “Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook,” Cancer Journal, vol. 18, no. 2, pp. 160–175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Quereux, M.-C. Pandolfino, A.-C. Knol et al., “Tissue prognostic markers for adoptive immunotherapy in melanoma,” European Journal of Dermatology, vol. 17, no. 4, pp. 295–301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. T. F. Gajewski, “Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment,” Clinical Cancer Research, vol. 13, no. 18, pp. 5256–5261, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. T. F. Gajewski, S. R. Woo, Y. Zha et al., “Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment,” Current Opinion in Immunology, vol. 25, no. 2, pp. 268–276, 2013. View at Google Scholar
  8. B. Dréno, J.-M. Nguyen, A. Khammari et al., “Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma,” Cancer Immunology, Immunotherapy, vol. 51, no. 10, pp. 539–546, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Khammari, J.-M. Nguyen, M. C. Pandolfino et al., “Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma,” Cancer Immunology, Immunotherapy, vol. 56, no. 11, pp. 1853–1860, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Jotereau, M.-C. Pandolfino, D. Boudart et al., “High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy,” Journal of Immunotherapy, vol. 10, no. 6, pp. 405–411, 1991. View at Google Scholar · View at Scopus
  11. M.-C. Pandolfino, N. Labarrière, M.-H. Tessier et al., “High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement,” Cancer Immunology, Immunotherapy, vol. 50, no. 3, pp. 134–140, 2001. View at Google Scholar · View at Scopus
  12. N. Gervois, F. Heuze, E. Diez, and F. Jotereau, “Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements,” European Journal of Immunology, vol. 20, no. 4, pp. 825–831, 1990. View at Publisher · View at Google Scholar · View at Scopus
  13. M. C. Pandolfino, S. Saïagh, A. C. Knol, and B. Dréno, “Comparison of three culture media for the establishment of melanoma cell lines,” Cytotechnology, vol. 62, no. 5, pp. 403–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Jung, U. Schauer, C. Heusser, C. Neumann, and C. Rieger, “Detection of intracellular cytokines by flow cytometry,” Journal of Immunological Methods, vol. 159, no. 1-2, pp. 197–207, 1993. View at Google Scholar · View at Scopus
  15. N. Chebassier, O. El Houssein, I. Viegas, and B. Dréno, “In vitro induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in keratinocytes by boron and manganese,” Experimental Dermatology, vol. 13, no. 8, pp. 484–490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Jarry, D. Masson, E. Cassagnau, S. Parois, C. Laboisse, and M. G. Denis, “Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E,” Molecular and Cellular Probes, vol. 18, no. 5, pp. 349–352, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Yeh, N. K. Karne, S. P. Kerkar et al., “Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma,” Ophthalmology, vol. 116, no. 5, pp. 981.e1–989.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Benlalam, V. Vignard, A. Khammari et al., “Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients,” Cancer Immunol Immunother, vol. 56, no. 4, pp. 515–526, 2007. View at Google Scholar
  19. Y. Godet, A. Moreau-Aubry, Y. Guilloux et al., “MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency,” Journal of Experimental Medicine, vol. 205, no. 11, pp. 2673–2682, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Labarrière, M.-C. Pandolfino, N. Gervois et al., “Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients,” Cancer Immunology, Immunotherapy, vol. 51, no. 10, pp. 532–538, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. A. C. Knol, J. M. Nguyen, M. C. Pandolfino et al., “Tissue biomarkers in melanoma patients treated with TIL,” PLoS One, vol. 7, no. 12, article e48729, 2012. View at Google Scholar
  22. A. C. Knol, J. M. Nguyen, G. Quéreux, A. Brocard, A. Khammari, and B. Dréno, “Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma,” Experimental Dermatology, vol. 20, no. 5, pp. 430–434, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. O. Hamid, H. Schmidt, A. Nissan et al., “A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma,” Journal of Translational Medicine, vol. 9, no. 1, article 204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Ribas, B. Comin-Anduix, J. S. Economou et al., “Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-Dioxygenase in Patients with Melanoma undergoing CTLA4 blockade,” Clinical Cancer Research, vol. 15, no. 1, pp. 390–399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. D. E. Gyorki, J. Yuan, Z. Mu et al., “Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma,” Annals of Surgical Oncology, vol. 20, no. 9, pp. 3106–3111, 2013. View at Google Scholar